CINECA IRIS Institutional Research Information System

CIRCOSTA, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.325
EU - Europa 1.564
AS - Asia 834
AF - Africa 34
SA - Sud America 20
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.790
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.259
IT - Italia 528
CN - Cina 321
SG - Singapore 237
IE - Irlanda 196
SE - Svezia 184
DE - Germania 152
GB - Regno Unito 81
FR - Francia 78
AT - Austria 73
UA - Ucraina 64
CA - Canada 63
FI - Finlandia 58
IN - India 54
VN - Vietnam 42
KR - Corea 35
PL - Polonia 32
HK - Hong Kong 31
ID - Indonesia 25
BE - Belgio 23
JP - Giappone 21
NL - Olanda 18
IR - Iran 17
SN - Senegal 15
BR - Brasile 13
AU - Australia 10
RU - Federazione Russa 10
PK - Pakistan 9
CZ - Repubblica Ceca 8
TW - Taiwan 8
CH - Svizzera 7
GR - Grecia 7
TR - Turchia 7
ZA - Sudafrica 7
DK - Danimarca 6
IQ - Iraq 6
NG - Nigeria 6
SA - Arabia Saudita 6
ES - Italia 5
HR - Croazia 5
PT - Portogallo 5
SK - Slovacchia (Repubblica Slovacca) 4
UZ - Uzbekistan 4
BG - Bulgaria 3
HU - Ungheria 3
RO - Romania 3
RS - Serbia 3
AR - Argentina 2
CI - Costa d'Avorio 2
CL - Cile 2
CO - Colombia 2
IL - Israele 2
JO - Giordania 2
MA - Marocco 2
MK - Macedonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BY - Bielorussia 1
BZ - Belize 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EG - Egitto 1
EU - Europa 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LV - Lettonia 1
MC - Monaco 1
MX - Messico 1
MY - Malesia 1
NP - Nepal 1
PH - Filippine 1
Totale 4.790
Salva come PNG Salva come JPEG
Città #
Chandler 375
Santa Clara 220
Dublin 193
Singapore 181
Beijing 116
Torino 105
Nyköping 97
Ashburn 81
Ann Arbor 80
Turin 77
Jacksonville 75
Vienna 73
Fairfield 63
Houston 56
Columbus 55
Medford 53
Woodbridge 53
Princeton 44
Redwood City 42
Dearborn 41
Wilmington 39
Fremont 37
Milan 35
Rome 26
Warsaw 26
Guangzhou 24
Jakarta 23
Brussels 22
Dong Ket 22
Seattle 22
Shanghai 22
Helsinki 21
Villeurbanne 21
Cambridge 20
New York 18
Washington 18
Québec 17
Ottawa 16
Boardman 15
Nanjing 14
Pisa 14
Menlo Park 13
Viterbo 13
Boston 11
London 11
Toronto 11
Bologna 10
Delhi 8
Los Angeles 8
Tai Wan 8
West Jordan 8
Amsterdam 7
Chengdu 7
Jinan 7
Montreal 7
Riverside 7
Rivoli 7
Uppsala 7
Abuja 6
Bari 6
Chennai 6
Epsom 6
Frankfurt am Main 6
Hangzhou 6
Hebei 6
Kunming 6
Naples 6
San Diego 6
Buffalo 5
Cassano Magnago 5
Catania 5
Dammam 5
Durban 5
Falls Church 5
Hefei 5
Lisbon 5
Munich 5
Novara 5
Nürnberg 5
Reston 5
San Jose 5
San Mateo 5
Valdagno 5
Zhengzhou 5
Bad Rappenau 4
Bratislava 4
Central 4
Central District 4
Chongqing 4
Florence 4
Gunzenhausen 4
Hamburg 4
Hong Kong 4
Hyderabad 4
Lappeenranta 4
Liverpool 4
Luni 4
Nichelino 4
Olomouc 4
Palermo 4
Totale 2.906
Salva come PNG Salva come JPEG
Nome #
PROCEEDINGS OF THE MERCK & ELSEVIER YOUNG CHEMISTSSYMPOSIUM 301
DHODH inhibitors and leukemia: an emergent interest for new myeloid differentiation agents 250
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors able to restore in vitro and in vivo myeloid differentiation 239
miR-223 is a coordinator of breast cancer progression as revealed by bioinformatics predictions 184
Identification of a new subclass of ALK negative ALCL expressing aberrant levels of ERBB4 transcripts 163
Development of Potent Human Dihydroorotate Dehydrogenase Inhibitors Able to Induces Myeloid Differentiation 162
The molecular and functional characterization of clonally expanded CD8 + TCR BV T cells in eosinophilic granulomatosis with polyangiitis (EGPA) 155
Clonal CD8+ TCR-Vbeta expanded populations with effector memory phenotype in Churg Strauss syndrome 124
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 119
TCR transfer induces TCR-mediated tonic inhibition of RAG genes in human T cells 118
Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors 118
Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia 118
A differentiating and apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 115
Nanocarriers as magic bullets in the treatment of leukemia 112
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold: SAR of the Biphenyl Moiety 105
High basal γH2AX levels sustain self-renewal of mouse embryonic and induced pluripotent stem cells 99
High Basal γH2AX Levels Sustain Self-Renewal of Mouse Embryonic and Induced Pluripotent Stem Cells. 98
In vitro myeloid differentiation using a new generation of potent human dihydroorotate dehydrogenase inhibitors 93
Functional phenotype of peripheral lymphocytes in Churg Strauss syndrome 90
CD100/Plexin-B1 interactions sustain proliferation and survival of normal and Leukemic CD5+ B lymphocytes 86
Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity 84
Targeting myeloid differentiation using potent human dihydroorotate dehydrogenase (hDHODH) inhibitors 84
Emerging therapies for acute myeloid leukaemia using hDHODH inhibitors 82
Differential effects on CLL cell survival exerted by different microenvironmental elements. 78
A differentiating and apoptotic therapy for acute myeloid leukaemia using potent human dihydroorotate dehydrogenase inhibitors. 78
Cytokine-induced killer cells engineered with exogenous t-cell receptors directed against melanoma antigens: Enhanced efficacy of effector cells endowed with a double mechanism of tumor recognition 75
Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms 74
A new pro-apoptotic therapy for Acute Myeloid Leukaemia using MEDS433, a potent human Dihydroorotate Dehydrogenase inhibitor 74
Molecular and Functional Analysis of Peripheral Lymphocytes in Churg Strauss Syndrome Reveals Several Monoclonal Expansions of CD8+Cells with a Th1/Proinflammatory Profile 71
The synergism between DHODH inhibitors and dipyridamole leads to metabolic lethality in acute myeloid leukemia 71
Improvement of in vivo pharmacokinetic profile of M433, a potent and innovative hDHODH inhibitor. 69
TCR gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naïve and memory T-cells without prior stimulation of endogenous TCR 65
The inhibition of human DHODH by M433 leads to differentiation and apoptosis in acute myeloid leukemia 63
Signalling through the sTCR/CD3 complex can regulate RAG1/RAG2 protein expression and TCR revision in mature human T lymphocytes 59
Meds433, a New Dihydroorotate Dehydrogenase Inhibitor, Induces Apoptosis and Differentiation in Acute Myeloid Leukemia 58
Signaling through the sTCR/CD3 complex can regulate RAG1/RAG2 protein expression and TCR revision in mature T lymphocytes 57
Apoptotic and differentiating therapy for AML using potent human dihydroorotate dehydrogenase inhibitor 56
Targeting chronic myeloid leukemia stem/progenitor cells using venetoclax-loaded immunoliposome 55
Improvement of metabolic weakness of new human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold 55
Hydroxylated heterocycles as a bioisosteric tool to Modulate the carboxylic function into design potent human Dihydroorotate Dehydrogenase inhibitors 55
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia 49
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 48
Targeting myeloid leukemias using human Dihydroorotate Dehydrogenase inhibitors based on 2-hydroxypyrazolo[1,5-a]pyridine scaffold: overcoming of metabolic issues 47
Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety 45
New human dihydroorotate dehydrogenase inhibitors able to restore myeloid differentiation in AML 44
Important steps into drug development of MEDS433, a potent human dihydroorotate dehydrogenase inhibitor based on the 2-hydroxypyrazolo[1,5-a]pyridine scaffold 40
Targeting Myeloid Leukemias Using human Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: Overcoming of Metabolic Issues 38
Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2- hydroxypyrazolo[1,5-a]pyridine scaffold: from academy to clinic 37
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across major human leukocyte antigen barriers 36
Important Steps into Drug Development of MEDS433, a Potent Human Dihydroorotate Dehydrogenase Inhibitor based on the 2-hydroxypyrazolo[1,5-a] Pyridine Scaffold 36
Investigation of the central core of MEDS433: A Bioisosteric voyage into the Amide's Role. 34
Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect 32
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 31
Enhancement of the metabolic stability in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase (hDHODH) 30
Overcoming of metabolic issues in 2-hydroxypyrazolo[1,5-a]pyridine scaffold-based inhibitors of human dihydroorotate dehydrogenase: the story of MEDS700 27
Investigation of the central core of MEDS433: A Bioisosteric voyage into the Amide's Role 21
Discovery of novel and potent human Dihydroorotate Dehydrogenase inhibitor that induces differentiation and apoptosis in Acute Myeloid Leukaemia 18
Improvement of Metabolic Weakness of New Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold to Target Myeloid Leukemias 18
Identification of a potent and innovative inhibitor of human Dihydroorotate Dehydrogenase, triggering differentiation and apoptosis in Acute Myeloid Leukaemia 17
Scaling up synthesis and in vivo evaluation of MEDS433: a promising preclinical candidate targeting AML 17
Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells 14
Discovery of novel and potent human Dihydroorotate Dehydrogenase inhibitor that induces differentiation and apoptosis in Acute Myeloid Leukaemia 13
Identification of a potent and innovative inhibitor of human Dihydroorotate Dehydrogenase, triggering differentiation and apoptosis in Acute Myeloid Leukaemia 13
Discovery of novel and potent human Dihydroorotate Dehydrogenase inhibitor that induces differentiation and apoptosis in Acute Myeloid Leukaemia 12
Totale 4.929
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.367
article - articoli 0
book - libri 0
conference - conferenze 9.575
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.942
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020340 0 0 0 0 0 66 81 34 32 53 49 25
2020/2021505 40 43 39 69 38 14 32 17 57 39 50 67
2021/2022653 22 15 41 49 33 36 43 31 20 71 183 109
2022/20231.202 101 142 39 122 95 284 82 69 106 45 71 46
2023/2024537 66 75 46 35 14 72 40 13 8 62 39 67
2024/2025872 45 71 101 200 330 125 0 0 0 0 0 0
Totale 4.929